Search alternatives:
significantly mediate » significantly mediated (Expand Search), significantly predicted (Expand Search), significantly mitigated (Expand Search)
mediate decrease » mean decrease (Expand Search), mediated defense (Expand Search)
higher decrease » higher degree (Expand Search), higher degrees (Expand Search), highest increase (Expand Search)
Showing 141 - 160 results of 6,355 for search '(( significantly mediate decrease ) OR ( significantly higher decrease ))', query time: 0.44s Refine Results
  1. 141
    BFD2 mediates brain inflammation induced in the acute stage of <i>T. gondii</i> infection.

    BFD2 mediates brain inflammation induced in the acute stage of <i>T. gondii</i> infection. by Xiaocheng Zhang (3140460)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 142
    nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU.

    nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU. by Peiqi Yin (6533747)

    Published 2025
    Save to List
    Saved in:
  3. 143
    <i>Porphyromonas gingivalis</i> LPS pretreated by ozone ultrafine bubble water induces decreased TLR2 activation.

    <i>Porphyromonas gingivalis</i> LPS pretreated by ozone ultrafine bubble water induces decreased TLR2 activation. by Mana Endo (22430706)

    Published 2025
    Save to List
    Saved in:
  4. 144
    Summary of post-treatment disease course measures from MDMA-AT publications.

    Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 145
    Study selection criteria.

    Study selection criteria. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 146
    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.

    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 147
    Disease course measures after the PTSD treatments.

    Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 148
    PICOS criteria for the SLR.

    PICOS criteria for the SLR. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 149
    Summary of post-treatment CAPS score changes from MDMA-AT publications.

    Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 150
    Summary of post-treatment disease course measures from off-label medications clinical trials.

    Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 151
    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.

    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 152
    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.

    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 153
    Summary of post-treatment disease course measures from clinical trials with psychotherapies.

    Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 154
    PRISMA flow chart.

    PRISMA flow chart. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 155
    Summary of clinical efficacy of relevant PTSD treatments.

    Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 156
    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.

    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 157
    Correlations between perceptual bias scores, age, and autism-associated features: Simple linear regression showing a significant correlation between elevated proprioceptive bias and:

    Correlations between perceptual bias scores, age, and autism-associated features: Simple linear regression showing a significant correlation between elevated proprioceptive bias an... by Daniel E. Lidstone (21567523)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 158
    RipE1 phosphorylation and NbUCH-mediated deubiquitination are independent mechanisms leading to RipE1 stability.

    RipE1 phosphorylation and NbUCH-mediated deubiquitination are independent mechanisms leading to RipE1 stability. by Wenjia Yu (9422059)

    Published 2025
    Save to List
    Saved in:
  19. 159
    Representative CEUS images with BR55 of mice with a subcutaneous tumour allograft (arrows) under treatment.

    Representative CEUS images with BR55 of mice with a subcutaneous tumour allograft (arrows) under treatment. by Felix L. Herr (21544362)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 160
    Column charts of SI<sub>8min</sub> and SI<sub>10min</sub> in the therapy and control group at follow-up.

    Column charts of SI<sub>8min</sub> and SI<sub>10min</sub> in the therapy and control group at follow-up. by Felix L. Herr (21544362)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: